Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.51
PLX's Cash to Debt is ranked lower than
85% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. PLX: 0.51 )
Ranked among companies with meaningful Cash to Debt only.
PLX' s Cash to Debt Range Over the Past 10 Years
Min: 0.51  Med: 10000.00 Max: No Debt
Current: 0.51
Equity to Asset -1.15
PLX's Equity to Asset is ranked lower than
97% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PLX: -1.15 )
Ranked among companies with meaningful Equity to Asset only.
PLX' s Equity to Asset Range Over the Past 10 Years
Min: -1.15  Med: -0.11 Max: 0.8
Current: -1.15
-1.15
0.8
F-Score: 2
Z-Score: -5.90
M-Score: -1.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -113.34
PLX's Operating margin (%) is ranked lower than
55% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. PLX: -113.34 )
Ranked among companies with meaningful Operating margin (%) only.
PLX' s Operating margin (%) Range Over the Past 10 Years
Min: -8239.43  Med: -435.62 Max: -35.36
Current: -113.34
-8239.43
-35.36
Net-margin (%) -137.71
PLX's Net-margin (%) is ranked lower than
57% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. PLX: -137.71 )
Ranked among companies with meaningful Net-margin (%) only.
PLX' s Net-margin (%) Range Over the Past 10 Years
Min: -8103.09  Med: -435.60 Max: -33.75
Current: -137.71
-8103.09
-33.75
ROA (%) -32.34
PLX's ROA (%) is ranked lower than
56% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. PLX: -32.34 )
Ranked among companies with meaningful ROA (%) only.
PLX' s ROA (%) Range Over the Past 10 Years
Min: -147.5  Med: -39.88 Max: -17.8
Current: -32.34
-147.5
-17.8
ROC (Joel Greenblatt) (%) -175.44
PLX's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. PLX: -175.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PLX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -988.83  Med: -251.80 Max: -70.4
Current: -175.44
-988.83
-70.4
Revenue Growth (3Y)(%) 17.00
PLX's Revenue Growth (3Y)(%) is ranked higher than
75% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. PLX: 17.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PLX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 236.2
Current: 17
0
236.2
EBITDA Growth (3Y)(%) -14.90
PLX's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. PLX: -14.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PLX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.6  Med: -13.35 Max: 84.2
Current: -14.9
-53.6
84.2
EPS Growth (3Y)(%) -9.30
PLX's EPS Growth (3Y)(%) is ranked lower than
55% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. PLX: -9.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PLX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.7  Med: -9.30 Max: 54.6
Current: -9.3
-49.7
54.6
» PLX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

PLX Guru Trades in

PLX Guru Trades in

PLX Guru Trades in

Q4 2015

PLX Guru Trades in Q4 2015

Jim Simons 20,933 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with PLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 4.35
PLX's P/S is ranked higher than
72% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.77 vs. PLX: 4.35 )
Ranked among companies with meaningful P/S only.
PLX' s P/S Range Over the Past 10 Years
Min: 4.19  Med: 31.53 Max: 748
Current: 4.35
4.19
748
Current Ratio 2.09
PLX's Current Ratio is ranked lower than
74% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. PLX: 2.09 )
Ranked among companies with meaningful Current Ratio only.
PLX' s Current Ratio Range Over the Past 10 Years
Min: 1.72  Med: 4.57 Max: 72.77
Current: 2.09
1.72
72.77
Quick Ratio 1.82
PLX's Quick Ratio is ranked lower than
72% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. PLX: 1.82 )
Ranked among companies with meaningful Quick Ratio only.
PLX' s Quick Ratio Range Over the Past 10 Years
Min: 1.45  Med: 4.57 Max: 72.77
Current: 1.82
1.45
72.77
Days Inventory 288.81
PLX's Days Inventory is ranked lower than
83% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. PLX: 288.81 )
Ranked among companies with meaningful Days Inventory only.
PLX' s Days Inventory Range Over the Past 10 Years
Min: 24.15  Med: 96.76 Max: 403.33
Current: 288.81
24.15
403.33
Days Sales Outstanding 98.52
PLX's Days Sales Outstanding is ranked lower than
69% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. PLX: 98.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
PLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.95  Med: 66.29 Max: 2016.91
Current: 98.52
14.95
2016.91
Days Payable 177.09
PLX's Days Payable is ranked higher than
81% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. PLX: 177.09 )
Ranked among companies with meaningful Days Payable only.
PLX' s Days Payable Range Over the Past 10 Years
Min: 159.3  Med: 347.75 Max: 4442.57
Current: 177.09
159.3
4442.57

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.15
PLX's Price/Median PS Value is ranked higher than
95% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. PLX: 0.15 )
Ranked among companies with meaningful Price/Median PS Value only.
PLX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.60 Max: 20.5
Current: 0.15
0.01
20.5
Price/Graham Number 0.40
PLX's Price/Graham Number is ranked higher than
88% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 3.04 vs. PLX: 0.40 )
Ranked among companies with meaningful Price/Graham Number only.
PLX' s Price/Graham Number Range Over the Past 10 Years
Min: 0.59  Med: 3.31 Max: 14.83
Current: 0.4
0.59
14.83
Earnings Yield (Greenblatt) (%) -16.92
PLX's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. PLX: -16.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PLX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -19.21  Med: 0.00 Max: 0
Current: -16.92
-19.21
0

More Statistics

Revenue(Mil) $17
EPS $ -0.24
Beta0.12
Short Percentage of Float1.13%
52-Week Range $0.74 - 2.35
Shares Outstanding(Mil)99.80

Analyst Estimate

Dec15
Revenue(Mil)
EPS($) -0.17
EPS without NRI($) -0.17

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PBD.Germany, PLX.Israel,
Protalix BioTherapeutics Inc was originally incorporated in the State of Florida in April 1992. It is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx. Using its ProCellEx system, it is developing a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of action. Its initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company has developed ElelysoTM, its first drug product, ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The Company is now also applying the properties of its ProCellEx system for the oral delivery of therapeutic proteins. The Company relies on a single approved supplier for certain materials relating to the current expression of its proprietary biotherapeutic proteins through ProCellEx. It faces competition from companies with approved treatments of Gaucher disease. Some such companies include iBio, Inc., Medicago Inc., and Greenovation Biotech GmbH. The Company has 94 pending patent applications and one joint pending patent application with a third party. The Company is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.
» More Articles for AMEX:PLX

Headlines

Articles On GuruFocus.com
Avago Technologies' Memory, FBAR, and Connectivity Business Will Take It Higher Oct 23 2014 
Weekly CFO Sells Highlight: AXP, CRAY, PLX, KMB, ITW, CATM, CAR May 07 2012 
Protalix BioTherapeutics Inc Reports Operating Results (10-K) Feb 23 2011 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Nov 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Oct 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Sep 08 2010 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 05 2010 
Protalix BioTherapeutics Inc (PLX) CEO and President David Aviezer sells 244,238 Shares Oct 21 2009 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 150,000 Shares Oct 19 2009 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 03 2009 

More From Other Websites
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Shareholder Director Nominations Jan 04 2016
Protalix Biotherapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 22 2015
PROTALIX BIOTHERAPEUTICS, INC. Financials Dec 08 2015
Is Protalix BioTherapeutics Inc. (PLX) A Good Stock To Buy? Nov 28 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Nov 23 2015
Protalix Meets FDA, To Start Phase III Fabry Disease Study Nov 17 2015
Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry... Nov 16 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Nov 16 2015
Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry... Nov 16 2015
Protalix reports 3Q loss Nov 09 2015
Protalix reports 3Q loss Nov 09 2015
Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results Nov 09 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Nov 09 2015
Protalix BioTherapeutics (PLX) Jumps: Stock Rises 8.7% Oct 26 2015
Pfizer Inc (PFE) Made Protalix BioTherapeutics, Inc. (PLX) Jump 11% Today Oct 23 2015
5 Stocks Under $10 Set to Soar Oct 22 2015
5 Stocks Insiders Love Right Now Oct 21 2015
Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease Oct 19 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Oct 19 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Oct 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK